Streetbeat News

Analyst Ratings

PGEN

JP Morgan analyst Brian Cheng initiates coverage on Precigen (NASDAQ:PGEN) with a Neutral rating.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 1:38 pm

FIVN

Roth MKM analyst Richard Baldry has reinstated a Buy rating on Five9 (NASDAQ:FIVN) and announced an $80 price target.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 1:36 pm

SILK

CL King analyst Kristen Stewart initiates coverage on Silk Road Medical (NASDAQ:SILK) with a Buy rating and announces a price target of $47.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 1:34 pm

IART

Citigroup analyst Joanne Wuensch downgrades Integra Lifesciences (NASDAQ:IART) from Neutral to Sell and lowers the price target from $59 to $39.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 1:32 pm

MIST

HC Wainwright & Co. analyst Patrick Trucchio reiterates a Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintains a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 1:30 pm

NXGN

Guggenheim analyst Jack Wallace maintains a Buy rating on NextGen Healthcare (NASDAQ:NXGN) but lowers the price target from $26 to $22.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 1:22 pm

SPOT

Guggenheim analyst Michael Morris maintains a Buy rating on Spotify Technology (NYSE:SPOT) and raises the price target from $165 to $180.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 1:21 pm

CWCO

Roth MKM analyst Gerry Sweeney maintains a Buy rating on Consolidated Water Co (NASDAQ:CWCO) and raises the price target from $21 to $24.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 1:19 pm

CFG

COLB

MC

Three high-yielding dividend stocks in the financial sector have been identified by Wall Street's most accurate analysts. These stocks are Citizens Financial Group (CFG), Moelis & Company (MC), and Columbia Banking System (COLB).

Portfolio Pulse from Lisa Levin

May 23, 2023 | 1:17 pm

BPMC

Guggenheim analyst Michael Schmidt maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $78 to $82.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 1:15 pm